Table 2.
Clinical and parasitological therapeutic outcome
AL (Ipinda site) | AS+AQ (Mlimba site) | |||||
End points | Before PCR corrections | After PCR corrections | Before PCR corrections | After PCR corrections | ||
With unresolved PCR | Without unresolved PCR | With unresolved PCR | Without unresolved PCR | |||
ETF | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1 (1.5) | 1 (1.6) | 1 (2.0) |
LCF | 1 (1.0) | 1 (1.1) | 0 (0.00) | 4 (6.1) | 3 (4.8) | 2 (4.2) |
LPF | 11 (12.0) | 5 (5.6) | 0 (0.00) | 19 (29.2) | 4 (6.5) | 0 (0.00) |
ACPR | 80 (87.0) | 83 (93.3) | 86 (100) | 41 (63.2) | 54 (87.1) | 45 (93.8) |
Total | 92 | 89 | 86 | 65 | 62 | 48 |